Letrozole in Oligospermia With Eugonadotropic-Hypogonadism and Low Testosterone Estradiol Ratio
Key facts
- Who runs it
- Mst.Sumyara Khatun
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 1 Jul 2023
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tab.Letrozole 2.5 mg once daily for 3 months
- Tab.Placebo once daily for 3 months
- Record updated
- 6 November 2026
Who can take part
- Age
- 20 years to 45 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Infertile male
- Age 20 -45 years,
- Oligospermia (sperm count < 10 million/ml) or azoospermia with low serum testosterone (<300 ng/dl), normal gonadotropin level (FSH, LH 2-7 IU/L), and low (<10:1) testosterone to estradiol ratio
Who cannot take part
- Previous chemotherapy or radiotherapy
- Concomitant use of anticonvulsants
- Antioxidant supplements in the previous 3 months
- Medical and endocrine disorders
- Genital diseases \& genital surgery
- Alcohol or substance abuse
- Androgens or antiandrogen
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if drug letrozole works to treat oligospermia in adults. It will also learn about the safety of drug letrozole. The main questions it aims to answer are:
Read full original descriptionShow less
Does drug letrozole improves semen parameter, serum restosterone, testosterone estradiol ratio in male with oligospermia.
What medical problems do participants have when taking drug letrozole? Researchers will compare drug letrozole to a placebo (a look-alike substance that contains no drug) to see if drug letrozole works to treat oligospermia..
Participants will:
Take drug letrozole or a placebo once daily for 3 months Visit the clinic three months after treatment
The 2 groups in the trial
- Experimental group:Letrozole 2.5 mg once daily for 3 monthsTreatment being tested
Tab.Letrozole 2.5 mg once daily for 3 months
Treatment: Tab.Letrozole 2.5 mg once daily for 3 months
- Comparator group: Placebo once daily for 3 monthsExisting treatment, for comparison
Tab.Placebo once daily for 3 months
Treatment: Tab.Placebo once daily for 3 months
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 November 2026